Synthesis of highly conjugated polymers

• US 20040022857A1
• Filed: 07/31/2002
• Published: 02/05/2004
• Est. Priority Date: 07/31/2002
• Status: Abandoned Application

• Current Assignee: General Electric Company
• Original Assignee: General Electric Company
• Inventors: Smith, Joanne F., Fish, Kenneth M., Moasser, Bahram, Uzgiris, Egidijus E.
• Application Number:
  US10/209,726
• Publication Number:
  US 20040022857A1
• Time in Patent Office: Days
• US Class Current: 424/486
• CPC Class Codes: A61K 49/0002 General or multifunctional contrast agents, e.g. chelated agents
• CPC Class Codes: A61K 49/085 conjugated systems
• CPC Class Codes: A61K 49/146 the peptide being a polyamino acid, e.g. poly-lysine

Abstract

Improved methods for forming substituted polymers having a high degree of conjugation include the steps of activating a steric hindrance molecule under conditions that ensure substantially all the steric hindrance molecules are mono-activated and then reacting with a polymer. An improved method for recovering polypeptides substituted with steric hindrance molecules and having an elongate configuration removes impurities and volatiles without achieving complete dryness of the copolymer.

Claims

1. A method comprising:

providing a substantially mono-activated steric hindrance molecule; and

reacting the substantially mono-activated steric hindrance molecule with a polymer,

to provide a polymer-steric hindrance molecule copolymer having an elongated structure and having a degree of conjugation of 90% or greater.

2. A method as in claim 1 wherein the steric hindrance molecule is a therapeutic agent.

3. A method as in claim 1 wherein the steric hindrance molecule is a targeting agent.

4. A method as in claim 1 wherein the steric hindrance molecule comprises an imaging agent.

5. A method as in claim 4 wherein the steric hindrance molecule chelates a paramagnetic entity.

6. A method as in claim 4 wherein the steric hindrance molecule chelates a lanthanide ion.

7. A method in claim 1 whrein the steric hindrance molecule is DTPA.

8. A method as in claim 1 wherein the polymer is a polypeptide.

9. A method as in claim 8 wherein the polypeptide is selected from the group consisting of polylysine, polyglutamic acid, polyaspartic acid and copolymers of lysine and either glutamic acid or aspartic acid.

25. A method of imaging a subject comprising the steps of:

reacting a conjugated polymer produced by the method of claim 1 with a image producing entity; and

introducing the resulting product into a blood vessel of said subject.

26. A method as in claim 25 wherein the image producing entity is a paramagnetic entity.

27. A method as in claim 25 wherein the image producing entity is a lanthanide ion.

10. A method comprising:

providing a substantially mono-activated lanthanide complexing molecule; and

reacting the substantially mono-activated lanthanide complexing molecule with a polypeptide.

11. The method of claim 10 wherein the step of providing a substantially mono-activated lanthanide ion complexing molecule comprises providing substantially mono-activated diethylenetriamine pentaacetic acid.

12. The method of claim 10 wherein the step of providing a substantially mono-activated lanthanide ion complexing molecule comprises providing an anhydride of diethylenetriamine pentaacetic acid.

13. The method of claim 12 wherein the step of providing an anhydride of diethylenetriamine pentaacetic acid activated with an amine comprises the steps of:

providing a solution containing diethylenetriamine pentaacetic acid and triethylamine;

cooling the solution to a temperature of about −

40°

C. or less; and

adding isobutyl chloroformate to the cooled solution.

14. The method of claim 10 wherein the step of reacting the substantially mono-activated lanthanide ion complexing molecule with a polypeptide comprises reacting the substantially mono-activated lanthanide ion complexing molecule with a polypeptide selected from the group consisting of polylysine, polyglutamic acid, polyaspartic acid and copolymers of lysine and either glutamic acid or aspartic acid.

15. The method of claim 10 wherein the step of reacting the substantially mono-activated lanthanide ion complexing molecule with a polypeptide comprises reacting the substantially mono-activated lanthanide ion complexing molecule with polylysine.

16. The method of claim 15 wherein the step of reacting the substantially mono-activated lanthanide ion complexing molecule with polylysine comprises adding the mono-activated lanthanide ion complexing molecule to an aqueous solution of polylysine.

17. The method of claim 10 further comprising the step of purifying the product produced by reacting the substantially mono-activated lanthanide ion complexing molecule with a polypeptide.

18. The method of claim 17 wherein the step of purifying the product produced by reacting the substantially mono-activated lanthanide ion complexing molecule with a polypeptide comprises removing impurities without substantially drying the product.

19. A lanthanide ion complexing molecule-polypeptide conjugate produced by the method of claim 10.

20. A method comprising:

providing a solution containing diethylenetriamine pentaacetic acid and triethylamine;

cooling the solution to a temperature of about −

40°

C. or less;

adding isobutyl chloroformate to the cooled solution to form a mono-anhydride of diethylenetriamine pentaacetic acid;

reacting the mono-anhydride of diethylenetriamine pentaacetic acid with a polypeptide containing lysine residues, whereby at least 90% of the lysine residues are substituted with diethylenetriamine pentaacetic acid groups.

21. The method of claim 20 wherein the step of reacting the substantially mono-activated diethylenetriamine pentaacetic acid with a polypeptide comprises reacting substantially mono-activated diethylenetriamine pentaacetic acid with polylysine.

22. The method of claim 20 further comprising the step of purifying the product produced by reacting the substantially mono-activated lanthanide ion complexing molecule with a polypeptide by removing impurities without substantially drying the product.

23. A diethylenetriamine pentaacetic acid-polypeptide conjugate produced by the method of claim 20.

28. A method of concentrated delivery of an imaging agent to a tumor of a subject comprising the steps of:

reacting a diethylenetriamine pentaacetic acid-polypeptide conjugate produced by the method of claim 20 with a paramagnetic entity; and

introducing the resulting product into a blood vessel of said subject.

24. A diethylenetriamine pentaacetic acid-ploysine conjugate having a degree of conjugation of about 95% or higher.

29. A method of purifying a conjugated polypeptide comprising the steps of:

subjecting a first composition to one or more purification processes without rendering the composition substantially dry, the first composition containing impurities and a polypeptide substituted with a steric hindrance molecule, the substituted polypeptide having an elongated configuration; and

recovering a purified composition containing the substituted polypeptide having an elongated configuration.

30. A method as in claim 29 wherein the step of subjecting the first composition to one or more purification processes without rendering the composition substantially dry comprises subjecting the first composition to one or more processes selected from the group consisting of evaporation, distillation, dialysis, centrifugation and ultrafiltration.

31. A method as in claim 29 wherein the first composition contains a polypeptide substituted with a steric hindrance molecule selected from the group consisting of diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrakis(2-propionic acid) (DOTMA), 1,4,8,11-tetraazacyclotetradecane-1,4,8,10-tetraacetic acid (TETA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(3-(4-carboxyl)-butanoic acid), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetic acid-methyl amide), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonic acid), and p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (pSCN-Bz-DOTA), bis(thiosemicarbazone), derivatives of bis(thiosemicarbazone), porphyrins, derivatives of porphyrins, 2,3-bis(2-thioacetamido)propionates, derivatives of 2,3-bis(2-thioacetamido)propionates, N,N′

-bis(mercaptoacetyl)-2,3-diaminopropanoate, bis(aminoethanethiol) and derivatives of bis(aminoethanethiol).